Estrogens in carcinoma of the prostate. Effects on enzymes and polypeptide hormones.
Patients with benign hyperplasia of the prostate and with anaplastic carcinoma have similar activities in their cells in staining for acid phosphatase. After therapy with estrogens the acid phosphatase is significantly inhibited, leucin amino peptidase and succinate dehydrogenase appear to be reactivated in the cells of anaplastic carcinoma. Serum TSH is decreased distinctly, serum levels of LH and prolactin are significantly elevated especially in patients with anaplastic carcinoma of the prostate in comparison to that of patients with treated benign hyperplasia.
D000135:Acid Phosphatase / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D002277:Carcinoma / Q000188:drug therapy / Q000378:metabolism*; D004798:Enzymes / Q000378:metabolism*; D004967:Estrogens / Q000494:pharmacology / Q000627:therapeutic use*; D005341:Fibrinolysin / Q000378:metabolism; D005640:Follicle Stimulating Hormone / Q000097:blood; D006728:Hormones / Q000378:metabolism*; D006801:Humans; D007931:Leucyl Aminopeptidase / Q000378:metabolism; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011388:Prolactin / Q000097:blood; D011470:Prostatic Hyperplasia / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D013385:Succinate Dehydrogenase / Q000378:metabolism; D013972:Thyrotropin / Q000097:blood
D002096:C-Peptide; D004798:Enzymes; D004967:Estrogens; D006728:Hormones; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin; D013385:Succinate Dehydrogenase; D000135:Acid Phosphatase; D007931:Leucyl Aminopeptidase; D005341:Fibrinolysin